Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...

Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...

Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

More than 90% of patients with PsA who received guselkumab every 8 weeks in the DISCOVER-2 trial maintained minimal ...

According to GlobalData’s Sales and Forecast database, total sales for Tremfya are expected to reach $7.8 billion globally by 2029.

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

You may report side effects to Health Canada at 1-866-234-2345. Before using guselkumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product ...